good points sarge but I believe will also need to do proper phase 2b as current phase 2a is not enough powered. But happy for statistician correct me.
also not forget data exclusivity should be available for NCE but not if take 505b2 Reg path in US which is strategy of SPL i think.
Ann: VIRALEZE relaunched by LloydsPharmacy in the UK, page-81
-
- There are more pages in this discussion • 173 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
0.001(1.03%) |
Mkt cap ! $40.97M | |||
| Open | High | Low | Value | Volume |
| 9.7¢ | 9.9¢ | 9.7¢ | $44.76K | 455.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 824859 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 121525 | 5 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |